They added that there is also overlap between the brain mechanisms that regulate overeating and those that contribute to the development and maintenance of substance use disorders, including AUD
[3] It is important to note that retatrutide has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) (MHRA medicines licensing database, accessed 2025
It is a dual GIP/GLP-1 receptor agonist, meaning it activates two hormone pathways instead of one, which is what distinguishes it from single-pathway GLP-1 drugs like semaglutide
If you are diabetic, monitor your blood sugar carefully on the day of and between infusions
If you proceed, verify pricing and pharmacy sourcing directly, screenshot the cancellation process, and set realistic expectations